CLINICAL TRIALS PROFILE FOR VENTOLIN HFA

505(b)(2) Clinical Trials for VENTOLIN HFA

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01323010 ↗	Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	N/A	2011-09-01	Metered dose inhalers with spacers are devices capable of providing higher rates of lung deposition of drugs such as beta agonists when compared to conventional nebulizers, but there is no consensus about the optimal dose when this is the device of choice and there is evidence that younger children need proportionally higher doses of albuterol (in μg/kg) when compared to older children. Other factors that may interfere with response to albuterol treatment include the genetics of the beta adrenergic receptor (ADRβ2) and infectious etiology of the wheezing attack. This study will assess the effectiveness of a dose regimen that prioritizes higher doses of albuterol, with doses in μg/kg higher for younger children. Security of this new dosing regimen will be assessed by monitoring clinical side effects and serum levels of albuterol, but the investigators will also examine the presence of 12 different respiratory viruses in these patients and evaluate the influence of ADRβ2 receptor genetics in the response to albuterol. The primary outcome measure will be the need for hospitalization. Secondary outcomes will include a change in clinical score, respiratory rate and forced expiratory volume in the first second, the need for additional treatments and length of stay in the emergency room for those not hospitalized.
New Dosage	NCT01323010 ↗	Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes	Completed	University of Sao Paulo	N/A	2011-09-01	Metered dose inhalers with spacers are devices capable of providing higher rates of lung deposition of drugs such as beta agonists when compared to conventional nebulizers, but there is no consensus about the optimal dose when this is the device of choice and there is evidence that younger children need proportionally higher doses of albuterol (in μg/kg) when compared to older children. Other factors that may interfere with response to albuterol treatment include the genetics of the beta adrenergic receptor (ADRβ2) and infectious etiology of the wheezing attack. This study will assess the effectiveness of a dose regimen that prioritizes higher doses of albuterol, with doses in μg/kg higher for younger children. Security of this new dosing regimen will be assessed by monitoring clinical side effects and serum levels of albuterol, but the investigators will also examine the presence of 12 different respiratory viruses in these patients and evaluate the influence of ADRβ2 receptor genetics in the response to albuterol. The primary outcome measure will be the need for hospitalization. Secondary outcomes will include a change in clinical score, respiratory rate and forced expiratory volume in the first second, the need for additional treatments and length of stay in the emergency room for those not hospitalized.
New Combination	NCT03906045 ↗	A Scintigraphy Study of PT010 in COPD Patients	Completed	Simbec Research	Phase 1	2019-04-04	This study is a single treatment period, single dose gamma scintigraphy study investigating the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF-MDI). This study will be investigating how the drug (known as PT010) is distributed in the lungs of Chronic Obstructive Pulmonary Disease (COPD) patients (with moderate to very severe COPD) following a maximal 10 second breath hold. This inhaler is intended to be used in the treatment of COPD, which is a group of diseases which cause lung problems and difficulty breathing. PT010 is a new combination product of 3 marketed drugs called Glycopyrronium, Formoterol Fumarate and Budesonide.

All Clinical Trials for VENTOLIN HFA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00102882 ↗	Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate	Completed	GlaxoSmithKline	Phase 4	2004-10-01	This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done during the study. Study medicines and procedures will be provided at no cost. Patients will be treated with VENTOLIN (8 wks), ATROVENT (8 wks), then ADVAIR or SEREVENT (16 wks). ADVAIR and SEREVENT are FDA approved for the treatment of asthma in patients 4 years of age and older.
NCT00180843 ↗	Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease	Terminated	GlaxoSmithKline	N/A	2005-09-01	Subjects undergo history, examination, lung function assessment after informed consent has been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is normal they will undergo a second and final scan four weeks later. If abnormal they will undergo two further scans with either nebulized bronchodilator or nebulized saline prior to their second and third scans. Each time they will have repeat lung function tests prior to scanning. We will examine the regional changes in ventilation and perfusion and there relationship to lung function.
NCT00180843 ↗	Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease	Terminated	Imperial College London	N/A	2005-09-01	Subjects undergo history, examination, lung function assessment after informed consent has been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is normal they will undergo a second and final scan four weeks later. If abnormal they will undergo two further scans with either nebulized bronchodilator or nebulized saline prior to their second and third scans. Each time they will have repeat lung function tests prior to scanning. We will examine the regional changes in ventilation and perfusion and there relationship to lung function.

Clinical Trial Conditions for VENTOLIN HFA

Condition Name

Condition Name for VENTOLIN HFA
Intervention	Trials
Asthma	22
Chronic Obstructive Pulmonary Disease	3
Asthma in Children	3

Condition MeSH

Condition MeSH for VENTOLIN HFA
Intervention	Trials
Asthma	23
Pulmonary Disease, Chronic Obstructive	5
Lung Diseases, Obstructive	4

Clinical Trial Locations for VENTOLIN HFA

Trials by Country

Trials by Country for VENTOLIN HFA
Location	Trials
United States	61
Canada	9
United Kingdom	7
China	4
Taiwan	3

Trials by US State

Trials by US State for VENTOLIN HFA
Location	Trials
New York	5
Oregon	4
Nebraska	3
Florida	3
California	3

Clinical Trial Progress for VENTOLIN HFA

Clinical Trial Phase

Clinical Trial Phase for VENTOLIN HFA
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	14
Phase 3	14

Clinical Trial Status

Clinical Trial Status for VENTOLIN HFA
Clinical Trial Phase	Trials
Completed	34
Terminated	5
RECRUITING	4

Clinical Trial Sponsors for VENTOLIN HFA

Sponsor Name

Sponsor Name for VENTOLIN HFA
Sponsor	Trials
GlaxoSmithKline	8
AstraZeneca	4
University of Dundee	2

Sponsor Type

Sponsor Type for VENTOLIN HFA
Sponsor	Trials
Other	58
Industry	28
NIH	1

VENTOLIN HFA Market Analysis and Financial Projection

Last updated: April 27, 2026

VENTOLIN HFA (albuterol sulfate) — Clinical Trials Update, Market Analysis, and Projection

What is Ventolin HFA and what product positions in the respiratory portfolio?

VENTOLIN HFA is a pressurized metered-dose inhaler (pMDI) formulation of albuterol sulfate (short-acting beta2-agonist, SABA) used for the rapid relief of bronchospasm in asthma and other reversible obstructive airway diseases. It is a long-established, off-patent brand in most major markets, with ongoing life-cycle activity that typically centers on formulation, delivery-device revisions, and labeling updates rather than new active-ingredient IP.

Because VENTOLIN HFA’s active ingredient is old and broadly genericized, the market outcome is driven less by patent protection and more by:

• Managed care contracting and formulary access
• Payer substitution to AB-rated generics
• Channel mix (retail vs mail vs institutional)
• Seasonality (respiratory infection-driven demand)
• Device- and refill-schedule economics (pMDIs versus alternatives like DPI)

---

What clinical trial activity is relevant for Ventolin HFA?

For products with an established active ingredient like albuterol, the clinical-trial “update” landscape typically falls into two categories: 1) Bioequivalence (BE) studies and comparative inhaler performance studies that support generic or authorized-label changes. 2) Real-world effectiveness and guideline-linked utilization analyses rather than large new efficacy trials.

Publicly posted trial records for albuterol sulfate and albuterol inhalers continue, but they rarely establish materially new efficacy endpoints for the active ingredient. Trial endpoints tend to validate:

• inhaler actuation consistency
• delivered dose distribution
• pharmacokinetic bridging in inhaled formats
• comparative bronchodilator response metrics under standardized challenge protocols

Practical investment read-through: in a SABA market, “clinical development” for VENTOLIN HFA is usually not a differentiator versus generics unless the sponsor holds a meaningful platform/device or specific authorized equivalence package that payers accept for preferred-tier placement.

---

What does the market look like for SABAs and where does Ventolin HFA fit?

VENTOLIN HFA competes in the broader SABA category, which is both:

• a high-volume, short-cycle therapy class used for acute symptom management
• a category under treatment paradigm pressure as guidelines increasingly steer maintenance away from sole SABA reliance

Demand drivers

• Asthma and COPD patient population size
• Acute symptom incidence
• Seasonal surges (winter respiratory infections)
• Payer incentives that push cost-efficient equivalents

Demand headwinds

• Persistent guideline shift to controller-inclusive regimens in asthma
• Uptake of alternatives (LABA-based regimens, ICS-containing strategies, and device preferences)
• Continued penetration of AB-rated generics for albuterol pMDIs

---

How does competitive pricing pressure affect Ventolin HFA?

Because albuterol is widely genericized, VENTOLIN HFA’s pricing power depends on whether it retains:

• preferred formulary status
• channel-based rebate structures
• contracted “brand-only” carve-outs (less common for older SABAs)
• pack size advantages that reduce per-actuation cost even when brand lists higher

Competitive dynamic

• If a payer can substitute AB-equivalent generics without loss of coverage, branded pMDIs typically face net price compression.
• Brand performance therefore tracks closely with payer-specific contracting and pharmacy benefit manager (PBM) formulary policy.

---

What does market projection mean for a mature SABA like Ventolin HFA?

For a mature SABA brand, “projection” usually means:

• stable-to-declining unit growth depending on patient population and guideline adherence trends
• net sales volatility tied to pricing and substitution rates
• modest upside from pack configuration and managed-care contracting

A credible projection framework for VENTOLIN HFA must include:

• Total category trend (asthma/COPD burden and acute utilization)
• Switching rate to generics for albuterol pMDIs
• Share shifts to other SABA delivery formats (where available) and to controller-inclusive regimens for asthma management

Directional base case: VENTOLIN HFA is likely to experience slower growth or net decline relative to the total respiratory market, with performance more influenced by reimbursement and substitution than by clinical differentiation.

---

Quantitative baseline: what scale indicators exist for Ventolin HFA and albuterol pMDIs?

Public market sizing by exact brand is often proprietary or inconsistent across vendors; however, the class-level picture is consistent across industry reporting: albuterol-containing inhalers remain a top acute-relief therapy line, with strong volume and high generic penetration.

For business planning, the actionable unit economics approach is to project VENTOLIN HFA using:

• category demand (patient use and seasonality)
• brand vs generic split
• net price after rebates
• average prescription counts and inhaler life expectancy (actuation per canister)

Because VENTOLIN HFA is a legacy product with broad generic availability, the most material lever is net price after payer rebates and substitution, not new clinical demand generation.

---

What is the regulatory and IP posture that drives market outlook?

VENTOLIN HFA’s active ingredient is not meaningfully protected in most markets by new-composition or new-method patents in a way that would block generics at scale. Life-cycle protections, when they exist, generally relate to:

• device-specific formulation or propellant configurations
• manufacturing process and regulatory data exclusivity (limited in scope)
• labeling or minor formulation changes

This IP posture makes the commercial outlook primarily sensitive to:

• AB-rating and interchangeability
• PBM substitution policies
• pack and device economics

---

Scenario projection for Ventolin HFA (industry-typical)

Below are scenario outlines suited to a mature, genericized SABA brand. These are not dependent on novel clinical readouts, and they focus on drivers that actually move branded SABA net sales.

Scenario	Category demand	Generic substitution intensity	Net price trend	Expected brand revenue trajectory
Downside	Stable to declining	High	Downward	Net sales decline, unit stability with net revenue erosion
Base case	Stable	Moderate	Flat to slightly down	Low single-digit decline or flat net sales
Upside	Stable to growing	Low (contracted)	Flat	Modest growth driven by contracting and mix

---

Key Takeaways

• VENTOLIN HFA is a mature albuterol sulfate pMDI (SABA) where clinical trial breakthroughs are not the core determinant of brand performance.
• Market trajectory is driven by generic substitution, PBM and formulary access, and net price after rebates, not by new efficacy evidence.
• Projections for a legacy branded SABA should be built on category utilization plus brand share and net pricing, with seasonality reflected in quarterly patterns.
• IP posture is generally not a strong moat for unit defense; commercial outcomes hinge on contracting and channel execution.

---

FAQs

1. Is Ventolin HFA protected by strong, blocking patents in major markets?
   No. The albuterol active ingredient is broadly genericized, so the branded moat is primarily formulary and contracting rather than active-ingredient patent exclusivity.

2. Do clinical trials materially change Ventolin HFA demand?
   Typically no. Trial activity for albuterol inhalers usually supports equivalence and device performance, not a step-change in clinical positioning.

3. What most affects Ventolin HFA net sales in a given year?
   Net price after rebates and the rate of substitution to AB-rated generics via PBM formularies.

4. How should seasonal effects be modeled for this product?
   Use winter respiratory infection peaks and spring/fall respiratory wave effects, then overlay payer utilization patterns by geography and channel.

5. What alternative therapies can steal SABA use in asthma?
   Controller-inclusive asthma regimens and guideline-driven strategies that reduce sole reliance on short-acting rescue monotherapy.

---

References (APA)

[1] ClinicalTrials.gov. (n.d.). Search results for albuterol sulfate inhalation studies. U.S. National Library of Medicine. https://clinicaltrials.gov/
[2] FDA. (n.d.). Ventolin HFA prescribing information (albuterol sulfate inhalation aerosol). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] Global Initiative for Asthma. (2024). Global Strategy for Asthma Management and Prevention. https://ginasthma.org/
[4] Global Initiative for Chronic Obstructive Lung Disease. (2024). Global Strategy for the Diagnosis, Management, and Prevention of COPD. https://goldcopd.org/
[5] U.S. FDA. (n.d.). Generic drug policy and interchangeability principles (AB rating framework). https://www.fda.gov/